(Based on a press release from NIH/National Cancer Institute)
The diagnostic test relied on computer software that detects key patterns of small proteins in the blood. Researchers analyzed serum proteins with mass spectroscopy, a technique used to sort proteins and other molecules based on their weight and electrical charge. They then used an artificial intelligence program developed by Correlogic Systems, Inc., in Bethesda, Md., to train a computer to identify patterns of proteins that differed between patients with prostate cancer and those in which a biopsy had found no evidence of disease. These patterns were identified using serum samples from 56 patients who had undergone a biopsy and whose disease status was known. Once established, the protein patterns were then used to predict diagnosis in a separate group of patients, whose biopsy results were not known by the researchers.... 'We have now demonstrated that combining proteomic technology with artificial intelligence based bioinformatics can be a powerful tool, and is a new paradigm in the detection and diagnosis of both ovarian and prostate cancers,' said Lance Liotta, M.D., Ph.D., the senior investigator on the study from NCI's Center for Cancer Research.